P2RY12 and coronary artery disorder: In fact, in our study 51.1% of the CAD patients are on dual anti-platelet treatment with aspirin and a P2Y12 receptor antagonist, and it has been demonstrated that P2Y12 antagonists potentiate the inhibitory actions of PGI2, which would be converted to TXA2 46.